Publication: A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines
dc.contributor.author | Dorota Smolarek | en_US |
dc.contributor.author | Claude Hattab | en_US |
dc.contributor.author | Gholamreza Hassanzadeh-Ghassabeh | en_US |
dc.contributor.author | Sylvie Cochet | en_US |
dc.contributor.author | Carlos Gutiérrez | en_US |
dc.contributor.author | Alexandre G. De Brevern | en_US |
dc.contributor.author | Rachanee Udomsangpetch | en_US |
dc.contributor.author | Julien Picot | en_US |
dc.contributor.author | Magdalena Grodecka | en_US |
dc.contributor.author | Kazimiera Wasniowska | en_US |
dc.contributor.author | Serge Muyldermans | en_US |
dc.contributor.author | Yves Colin | en_US |
dc.contributor.author | Caroline Le Van Kim | en_US |
dc.contributor.author | Marcin Czerwinski | en_US |
dc.contributor.author | Olivier Bertrand | en_US |
dc.contributor.other | Inserm | en_US |
dc.contributor.other | Ludwik Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences | en_US |
dc.contributor.other | Institut National de la Transfusion Sanguine | en_US |
dc.contributor.other | Universite Paris 7- Denis Diderot | en_US |
dc.contributor.other | Vrije Universiteit Brussel | en_US |
dc.contributor.other | Flanders Interuniversity Institute for Biotechnology | en_US |
dc.contributor.other | Universidad de Las Palmas de Gran Canaria | en_US |
dc.contributor.other | Mahidol University | en_US |
dc.date.accessioned | 2018-09-24T08:42:50Z | |
dc.date.available | 2018-09-24T08:42:50Z | |
dc.date.issued | 2010-10-01 | en_US |
dc.description.abstract | Fy blood group antigens are carried by the Duffy antigen receptor for chemokines (DARC), a red cells receptor for Plasmodium vivax broadly implicated in human health and diseases. Recombinant VHHs, or nanobodies, the smallest intact antigen binding fragment derivative from the heavy chain-only antibodies present in camelids, were prepared from a dromedary immunized against DARC N-terminal extracellular domain and selected for DARC binding. A described VHH, CA52, does recognize native DARC on cells. It inhibits P. vivax invasion of erythrocytes and displaces interleukin-8 bound to DARC. The targeted epitope overlaps the well-defined DARC Fy6 epitope. KDof CA52-DARC equilibrium is sub-nanomolar, hence ideal to develop diagnostic or therapeutic compounds. Immunocapture by immobilized CA52 yielded highly purified DARC from engineered K562 cells. This first report on a VHH with specificity for a red blood cell protein exemplifies VHHs' potentialities to target, to purify, and to modulate the function of cellular markers. © 2010 Springer Basel AG. | en_US |
dc.identifier.citation | Cellular and Molecular Life Sciences. Vol.67, No.19 (2010), 3371-3387 | en_US |
dc.identifier.doi | 10.1007/s00018-010-0387-6 | en_US |
dc.identifier.issn | 14209071 | en_US |
dc.identifier.issn | 1420682X | en_US |
dc.identifier.other | 2-s2.0-77956759905 | en_US |
dc.identifier.uri | https://repository.li.mahidol.ac.th/handle/20.500.14594/28636 | |
dc.rights | Mahidol University | en_US |
dc.rights.holder | SCOPUS | en_US |
dc.source.uri | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956759905&origin=inward | en_US |
dc.subject | Biochemistry, Genetics and Molecular Biology | en_US |
dc.subject | Neuroscience | en_US |
dc.subject | Pharmacology, Toxicology and Pharmaceutics | en_US |
dc.title | A recombinant dromedary antibody fragment (VHH or nanobody) directed against human Duffy antigen receptor for chemokines | en_US |
dc.type | Article | en_US |
dspace.entity.type | Publication | |
mu.datasource.scopus | https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=77956759905&origin=inward | en_US |